echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The new lysovirus shows early efficacy.

    The new lysovirus shows early efficacy.

    • Last Update: 2020-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    News Today U.S. biotech company Replimune announced that it will disclose the first clinical advances in two ovomavirus (OV) therapies at this year's HITC annual meeting.
    generation HSV lysovirus RP1 and Opdivo are used in several skin cancers to produce higher response rates, including 87.5% ORR and 62.5% CR in CSCC, including remote tumors without direct injection of OV.
    a more complex second-generation therapy, RP2, produced a 50% partial response rate in 6 patients with different solid tumors, including far-end tumors that did not inject OV directly.
    patients who responded had blackness, saliva-gland mucus epidertic cancer, and esophageal cancer.
    trials using a combination of RP2 and O drugs are recruiting patients.
    ov technology platform called Immulytic, which analyzes the source of the drug, can be seen in both immunity and lethality.
    This platform is based on HSV and simultaneously expresses granulocyte-macrophage cluster stimulation factor (GM-CSF) and a cell fusion protein called GALV-GP-R to enhance immune response and promote bystander killing.
    HSV not only has strong tumor activity, but also can insert some immune activation or other proteins that destroy tumor tissue, so it is now the main lysosovirus.
    T-VEC, which expresses GM-CSF, has been marketed for blackness, so at least the basic skeleton of intra-tumor injection of this therapy has proven safe and effective.
    its second-generation product PR2 added a protein similar to CTLA4 antibodies to further activate the immune activity of the tumor micro-environment.
    this year's new crown epidemic has made the virus a topic of concern.
    cells that express ACE2 from a new coronary infection, when the virus in the infected cell replicates to a certain extent, it causes cell death.
    scientists have long hoped to use the virus as a destructive nature to selectively kill tumors, but also invented a number of use of tumor cells high expression enzyme virus amplification mechanism.
    passive OV treatment may have occurred early, very few patients with advanced metastasis tumors can recover without any therapy, according to statistics, most of these cases are related to infection.
    In addition to tumors, the virus can also inhibit other viral infections, and this year it has been reported that HCV can inhibit the proliferation of HBV, so if you find a virus that is safer than hepatitis C, you can also use this anodesgeometer to control hepatitis B infection.
    directly killing tumor cells is only one of the working mechanisms of OV.
    virus infection usually activates the natural and after-life immune system, because fighting viral infection is already one of the system's own work, so further increase the pressure on the survival of the tumor.
    immune system activates, it is not only effective for treating point tumors, but may also produce systemic tumor control activity.
    this is why OV can treat advanced metastasis tumors even though it now relies largely on intra-tumor injections, which is somewhat similar to radiotherapy.
    natural immune response induced by viral infection usually increases the expression of checkpoints such as PD-L1, so it is more effective in combination with PD-1 drugs, which is why they are used in combination with O drugs.
    PR2 also hides a CTLA4 blocking protein, a bit of a grass-roots stand.
    this strategy may seem tempting, there are many practical obstacles.
    The first immunotherapy and viral therapy are already a bit conflicted, because one of the immune system's responsibilities is to get rid of the virus, which is like getting the police and robbers to work together on a mission (illustrated from the film Blue Streak, which interested readers can search for).
    but there are always loopholes in any system, such as the new crown, which prevents the activation of the natural immune system in some populations at least in the early stages of infection.
    so as long as you screen enough systems to avoid the problem, at least you may find enough windows between clearing tumors and clearing OVs.
    but there is also a potential risk that avoiding the immune system too successfully could cause long-term infections in patients, especially in older patients with compromised immune systems.
    is a common problem faced by all natural immune system activator therapies, which is the toxicity of systemic dosing.
    natural immune system is an alarm system that can only be used in specific locations where serious disasters occur, and if rescue trains go door-to-door to water society, it's a mess.
    systemic dosing is not only more toxic, but also accelerates the removal of the host OV, so now OV can only be given in-tumor, fortunately, there are many solid tumors can now use this drug treatment technology.
    drugs targeting key components of the virus response system, such as STING and TLR, do not need to be live viruses and are now at the forefront of popular immunotherapy.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.